Truist Securities Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX)
Tweet Send to a Friend
Truist Securities analyst Les Sulewski reiterated a Buy rating and $10.00 price target on Amneal Pharmaceuticals (NASDAQ: AMRX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
